Trial Profile

A Post-Marketing Clinical Study to Evaluate the Safety of Elunate (Fruquintinib Capsules) in Chinese Patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fruquintinib (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Hutchison MediPharma; HUTCHMED

Most Recent Events

06 Jun 2023 Results (From April 2019 to Feb 2022) assessing the safety of Fruquintinib in real-world clinical practice in China, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
25 May 2023 ording to a HUTCHMED media release, data from this study will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
15 Dec 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com